Failure of Dupilimab with Severe Prurigo Nodularis That Responded Well to Abrocitinib
Dermatitis® · 2023
DOI: 10.1089/derm.2022.0065 ↗Kurz gefasst
Leserbrief in der Zeitschrift Dermatitis®, 2023. Verfasst von Ashley Vander Does und 1 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Phillip Frost Department of Dermatology and Miami Itch Center, University of Miami, Miami, FL, USA. Hauptthemen laut MEDLINE: Prurigo, Neurodermatitis. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dr. Phillip Frost Department of Dermatology and Miami Itch Center, University of Miami, Miami, FL, USA.
Zitieren
APA
Vander Does, A., & Yosipovitch, G. (2023). Failure of Dupilimab with Severe Prurigo Nodularis That Responded Well to Abrocitinib. Dermatitis®. https://doi.org/10.1089/derm.2022.0065
Vancouver
Vander Does A, Yosipovitch G. Failure of Dupilimab with Severe Prurigo Nodularis That Responded Well to Abrocitinib. Dermatitis®. 2023. doi:10.1089/derm.2022.0065
BibTeX
@article{VanderDoes2023,
author = {Vander Does, Ashley and Yosipovitch, Gil},
title = {Failure of Dupilimab with Severe Prurigo Nodularis That Responded Well to Abrocitinib},
journal = {Dermatitis®},
year = {2023},
doi = {10.1089/derm.2022.0065}
}
EUVIMED